Brixmor (NYSE: BRX) is a real estate investment trust (REIT) that owns and operates a high-quality, national portfolio of open-air shopping centers. Its 363 retail centers comprise approximately 64 million square feet of prime retail space in established trade areas. The Company strives to own and operate shopping centers that reflect Brixmor's vision "to be the center of the communities we serve" and are home to a diverse mix of thriving national, regional and local retailers. Brixmor is a proud real estate partner to over 5,000 retailers including The TJX Companies, The Kroger Co., Publix Super Markets and Ross Stores.

Brixmor Property Group Inc.

Evercore ISI analyst Michael Griffin CFA maintained a Buy rating on Brixmor Property today and set a price target of $34.00. Griffin CFA covers the...

Evercore ISI Remains a Buy on Brixmor Property (BRX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alpha Cognition Inc (ACOG), Zenas BioPharma, Inc. (Z...

Analysts Are Bullish on Top Healthcare Stocks: Alpha Cognition Inc (ACOG), Zenas BioPharma, Inc. (ZBIO)

ImmunityBio ( ($IBRX) ) has issued an announcement. On June 9, 2026, ImmunityBio, Inc. held its 2026 Annual Meeting of Stockholders, with approxima...

ImmunityBio Shareholders Reelect Board at 2026 Annual Meeting

LB Pharmaceuticals, Inc. ( ($LBRX) ) has shared an announcement. LB Pharmaceuticals, Inc. reported the results of its 2026 Annual Meeting of Stockh...

LB Pharmaceuticals Stockholders Approve Directors and Auditor

Belararox Ltd. ( ($AU:BRX) ) just unveiled an announcement. Belararox Ltd. has called a General Meeting of shareholders to be held in Perth on 10 J...

Belararox Moves to Digital Communications Ahead of July Shareholder Meeting

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on LB Pharmaceuticals, Inc., with a price target of $45.00. ...

H.C. Wainwright Sticks to Their Buy Rating for LB Pharmaceuticals, Inc. (LBRX)

Immunitybio Inc ($IBRX) announced an update on their ongoing clinical study. The study, titled “Open-Label, Single-Arm Phase 2 Study Of Nogapendeki...

ImmunityBio Advances HPV-Positive Head and Neck Cancer Trial, Setting Up a New Catalyst for IBRX Investors

Forte Biosciences ( ($FBRX) ) just unveiled an announcement. At its 2026 annual meeting of stockholders held on May 29, 2026, Forte Biosciences, In...

Forte Biosciences Shareholders Approve Directors and Governance Items

Moleculin Biotech ( ($MBRX) ) has provided an announcement. On May 29, 2026, Moleculin Biotech reported new clinical data at the 2026 ASCO Annual M...

Moleculin Highlights Annamycin Cardiac Safety Data at ASCO

An update from Belararox Ltd. ( ($AU:BRX) ) is now available. Belararox Ltd. has advised that 38,716,761 quoted options exercisable at $0.66 will e...

Belararox options set to expire deeply out of the money

Belararox Ltd. ( ($AU:BRX) ) has issued an update. Belararox Ltd. has issued 56,124,856 fully paid ordinary shares following the completion of a pl...

Belararox Expands Capital Base With New Share Issuance

Belararox Ltd. ( ($AU:BRX) ) has shared an announcement. Belararox Ltd has applied to the ASX for quotation of 6,124,857 new ordinary fully paid sh...

Belararox Seeks ASX Quotation for Shares Issued to Contractors

Belararox Ltd. ( ($AU:BRX) ) has provided an update. Belararox Ltd. has applied to the Australian Securities Exchange for quotation of 49,999,999 o...

Belararox Seeks ASX Quotation for 50 Million New Shares

In a report released today, Michael Lewis from Truist Financial maintained a Buy rating on Brixmor Property, with a price target of $33.00. Lewis c...

Truist Financial Reaffirms Their Buy Rating on Brixmor Property (BRX)

Analysts have been eager to weigh in on the Real Estate sector with new ratings on Welltower (WELL), Brixmor Property (BRX) and Charter Hall Group ...

Analysts Offer Insights on Real Estate Companies: Welltower (WELL), Brixmor Property (BRX) and Charter Hall Group (OtherCTOUF)

Moleculin Biotech ( ($MBRX) ) just unveiled an announcement. On May 21, 2026, Moleculin Biotech announced that an abstract featuring pooled cardiac...

Current Quarter	$0.58	Next Quarter	$0.59
Current Year	$2.36	Next Year	$2.48
QoQ Growth	+1.7%	YoY Growth	+5.1%
3Y EPS CAGR	+2.2%	Target Price	$33.33
Consensus	Buy	Upside	+7.8%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BRX	$30.91	-0.13%	3.61M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BRX	$30.91	-0.1%	3.61M
3
4
5
6

BRX

BRX

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Brixmor Property Group Inc. Data in Excel

Get Brixmor Property Group Inc. Data in Excel